Authors
Latest:
Two Gene Therapies Fix Fault in Sickle Cell Disease and ß-thalassemiaTwo gene therapy techniques in separate, concurrently published trials demonstrate clinical success in mitigating monogenic hemoglobinopathies.
Latest:
Stem Cell Therapy Reverses Type 1 DiabetesA novel treatment method called stem cell educator therapy appears to reverse the effects of type 1 diabetes, researchers at the University of Illinois at Chicago and colleagues in China report.
Latest:
Bendamustine Plus Rituximab Bests Current Standard of Care for Indolent LymphomaBendamustine (Treanda) plus rituximab (Rituxan; B/R) was superior to CHOP plus rituximab (CHOP-R) as first-line therapy of indolent lymphoma and mantle cell lymphoma in a multicenter, randomized, controlled trial of the German Study Group on Indolent Lymphoma (StiL). At an oral presentation at the 51st ASH Annual Meeting, experts agreed that this study may be practice-changing.
Latest:
Dr. Margulis on Different Approaches to Adjuvant Therapy in RCCVitaly Margulis, MD, assistant professor of Urologic Oncology, UT Southwestern Medical Center, discusses 2 different approaches to administering adjuvant therapy for patients with renal cell carcinoma.
Latest:
Dr. Harshman on Earlier Use of Immunotherapy in RCCLauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).
Latest:
Dr. Urbanic on the Evolution of Radiation in NSCLCJames Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the evolution of radiation therapy in the treatment of patients with oligometastatic non–small cell lung cancer.
Latest:
Dr. McGregor on Whether Patients Need Frontline Combinations in RCCBradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.
Latest:
Dr. Pinilla-Ibarz on the FDA Approval of Moxetumomab Pasudotox in Hairy Cell LeukemiaJavier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the FDA approval of moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.
Latest:
Dr. Forster on Next Steps With Lurbinectedin in SCLCMartin Forster, MD, a medical oncologist, University College London Hospitals, discusses the next steps with the investigational agent lurbinectedin in combination with doxorubicin as a second-line therapy for patients with small cell lung cancer (SCLC).
Latest:
Dr. Meric-Bernstam on the Activity of Telaglenastat and Cabozantinib in mRCCFunda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics, medical director of the Institute for Personalized Cancer Therapy, and a professor in the Divisions of Cancer Medicine and Surgery at The University of Texas MD Anderson Cancer Center, discusses the activity of the combination of telaglenastat (CB-839) and cabozantinib (Cabometyx) in heavily pretreated patients with metastatic renal cell carcinoma (mRCC).
Latest:
Dr. Rischin on KEYNOTE-048 Results in Head and Neck Squamous Cell CarcinomaDanny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the phase III KEYNOTE-048 trial, which examines pembrolizumab or pembrolizumab plus chemotherapy versus EXTREME as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma.
Latest:
Dr. Chao on Minimal Residual Disease in ALLNelson Jen An Chao, MD, professor of medicine, Donald D. and Elizabeth G. Cooke Cancer Research Professor, chief, Division of Cell Therapy in the Department of Medicine, Duke Cancer Institute, discusses minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).
Latest:
Dr. Barocas on Adjuvant Sunitinib in Renal Cell CarcinomaDaniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.
Latest:
Dr. Allan on the Use of Vecabrutinib Therapy in B-Cell MalignanciesJohn N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.
Latest:
Dr. Alva on the Shift Toward Combination Therapy in mRCCAjjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.
Latest:
Dr. Vaishampayan on Systemic Therapy Followed by Cytoreductive Nephrectomy in mRCCUlka Vaishampayan, MD, discusses the considerations when giving patients with metastatic renal cell carcinoma systemic therapy followed by cytoreductive nephrectomy.
Latest:
Dr. Goldman on Targeted Therapy Options for EGFR-, ALK-, and ROS1-Mutated NSCLCJonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.
Latest:
Dr. Reckamp on Targeted Therapy Options for Rare Mutations in NSCLCKaren L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.
Latest:
Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLCTerence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.
Latest:
Dr. Goy on the Clinical Implications of CAR T-Cell Therapy in MCLAndre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.
Latest:
AGS-003 to Be Tested With Sunitinib as RCC TreatmentA trial (NCT01582672) that will pair a targeted treatment with a vaccine therapy for firstline treatment of renal cell carcinoma (RCC) is recruiting at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute.
Latest:
ASCO 2016: Natural Killer Cell-Based Therapies in Blood CancersAs part of our coverage of the annual ASCO conference, we spoke with Dr. Veronika Bachanova on the role of NK cell therapy in hematologic malignancies.
Latest:
Adjuvant Therapy for Non-Small Cell Lung Cancer: Impact of Recent Clinical Trials on Community PracticeNon-small cell lung cancer (NSCLC) is diagnosed at an early stage, when it is amenable to surgical resection in approximately 20% to 25% of cases.
Latest:
Cytoreductive Nephrectomy, Immunotherapy-Based Systemic Therapy Induce Benefit in mRCCA pooled analysis compared survival among patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy and either targeted therapy or immunotherapy regimens utilizing checkpoint inhibitors.
Latest:
Should maintenance therapy serve as the standard of care in metastatic non-small-cell lung cancer?Patients with incurable NSCLC are less likely to progress to second-linetherapy with the right maintenance regimen. But maintenance therapyalso means committing patients to continuous treatment without anybreaks or chances to recover from adverse events.
Latest:
R-CHOP is standard of care for advanced DLBCL patientsRituximab (Rituxan) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard induction therapy for patients with advanced-stage diffuse large B-cell lymphoma, including both elderly and younger patients.
Latest:
Results of High-Dose Therapy and Autologous Stem Cell Transplant in Patients With Stage IV Hodgkin’s Disease: The Impact of Disease Status and Prior RadiotherapyAbout 20%-50% of patients with stage IV Hodgkin’s disease may suffer a relapse after initial chemotherapy-induced remission. Consolidative radiotherapy has been used in combination with chemotherapy to reduce relapse at areas of initial bulky disease; however, no survival benefit has been shown in the few randomized studies.
